New Delhi: Drug major Cipla on Wednesday said it has received approval from the US health regulator to market a generic drug used to treat acromegaly and other conditions.
The company has received final approval from the US Food and Drug Administration (USFDA) to market Lanreotide Injection in multiple strengths, the Mumbai-based drugmaker said in a statement.
It said the company's lanreotide injection is a therapeutically equivalent generic version of Somatulin Depot Injection.
The drugmaker said its product is suitable for treating patients with acromegaly and gastroenteropancreatic neuroendocrine tumors.
According to IQVIA (IMS Health), Somatulin Depot had sales of approximately US$89 million for the 12-month period ending March 2024.
The company has received final approval from the US Food and Drug Administration (USFDA) to market Lanreotide Injection in multiple strengths, the Mumbai-based drugmaker said in a statement.
It said the company's lanreotide injection is a therapeutically equivalent generic version of Somatulin Depot Injection.
The drugmaker said its product is suitable for treating patients with acromegaly and gastroenteropancreatic neuroendocrine tumors.
According to IQVIA (IMS Health), Somatulin Depot had sales of approximately US$89 million for the 12-month period ending March 2024.
